Advanced Proteome Therapeutics Corporation

TSXV:APC.H Stock Report

Market Cap: CA$205.6k

Advanced Proteome Therapeutics Past Earnings Performance

Past criteria checks 0/6

Advanced Proteome Therapeutics's earnings have been declining at an average annual rate of -307%, while the Biotechs industry saw earnings growing at 20.3% annually.

Key information

-307.0%

Earnings growth rate

-298.8%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Apr 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Advanced Proteome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:APC.H Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 230-201
31 Jan 230-101
31 Oct 220001
31 Jul 220101
30 Apr 220101
31 Jan 220001
31 Oct 210-101
31 Jul 210-200
30 Apr 210-210
31 Jan 210-110
31 Oct 200-110
31 Jul 200010
30 Apr 200010
31 Jan 200010
31 Oct 190010
31 Jul 190010
30 Apr 190010
31 Jan 190010
31 Oct 180-110
31 Jul 180-110
30 Apr 180010
31 Jan 180-110
31 Oct 170-110
31 Jul 170-110
30 Apr 170-110
31 Jan 170-110
31 Oct 160-110
31 Jul 160-110
30 Apr 160-110
31 Jan 160-110
31 Oct 150-110
31 Jul 150-110
30 Apr 150010
31 Jan 150010
31 Oct 140-110
31 Jul 140-110
30 Apr 140-210
31 Jan 140-210

Quality Earnings: APC.H is currently unprofitable.

Growing Profit Margin: APC.H is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if APC.H's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare APC.H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APC.H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: APC.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies